Literature DB >> 19910636

Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins.

Carlos O Mendivil1, Chunyu Zheng, Jeremy Furtado, Julian Lel, Frank M Sacks.   

Abstract

OBJECTIVE: We aimed to clarify the influence of apolipoprotein C-III (apoCIII) on human apolipoprotein B metabolism. METHODS AND
RESULTS: We studied the kinetics of 4 very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) types containing: (1) otherApos-CIII-: none of apoCIII, apoAII, apoCI, apoCII, or apoE; (2) otherApos+CIII-: no apoCIII but at least one of the others; (3) otherApos-CIII+: apoCIII, but not any others; and (4) otherApos+CIII+: apoCIII and at least one other. VLDL and IDL otherApos-CIII+ and otherApos-CIII- had similar rates of lipolytic conversion to smaller particles. However, light LDL otherApos-CIII+ compared with otherApos-CIII- had much faster conversion to dense LDL as did light LDL otherApos+CIII+ compared with otherApos+CIII-. VLDL and IDL otherApos-CIII+ had minimal direct removal from circulation, whereas VLDL and IDL otherApos+CIII-, rich in apoE, showed fast clearance. Lipoproteins in fraction otherApos+CIII+ also rich in apoE had very low clearance.
CONCLUSIONS: The results suggest that apoCIII strongly inhibits hepatic uptake of VLDL and IDL overriding the opposite influence of apoE when both are present. The presence of apoCIII on dense VLDL is not associated with slow conversion to IDL, a lipoprotein lipase-dependent process; but when on light LDL, apoCIII is associated with enhanced conversion to dense LDL, a process involving hepatic lipase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910636      PMCID: PMC2818784          DOI: 10.1161/ATVBAHA.109.197830

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  34 in total

Review 1.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond.

Authors:  R W Mahley; Y Huang
Journal:  Curr Opin Lipidol       Date:  1999-06       Impact factor: 4.776

Review 2.  Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease.

Authors:  H B Brewer
Journal:  Am J Cardiol       Date:  1999-05-13       Impact factor: 2.778

3.  Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism.

Authors:  Sonia Dugué-Pujol; Xavier Rousset; Danièle Pastier; Nhuan Tran Quang; Virginie Pautre; Jean Chambaz; Michèle Chabert; Athina-Despina Kalopissis
Journal:  J Lipid Res       Date:  2006-09-21       Impact factor: 5.922

4.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.

Authors:  Chunyu Zheng; Christina Khoo; Katsunori Ikewaki; Frank M Sacks
Journal:  J Lipid Res       Date:  2007-02-21       Impact factor: 5.922

6.  In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.

Authors:  M C Jong; V E Dahlmans; P J van Gorp; K W van Dijk; M L Breuer; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

7.  Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III.

Authors:  Chunyu Zheng; Christina Khoo; Jeremy Furtado; Katsunori Ikewaki; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2008-08       Impact factor: 7.045

8.  Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial.

Authors:  Jeremy D Furtado; Hannia Campos; Lawrence J Appel; Edgar R Miller; Nancy Laranjo; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2008-06       Impact factor: 7.045

9.  Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma.

Authors:  Minh N Nguyen; Dick C Chan; Kevin P Dwyer; Paul Bolitho; Gerald F Watts; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2006-03-23       Impact factor: 5.922

Review 10.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

Authors:  Esther M M Ooi; P Hugh R Barrett; Dick C Chan; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2008-05       Impact factor: 6.124

View more
  54 in total

1.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

2.  Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.

Authors:  Jeremy D Furtado; Mark K Wedel; Frank M Sacks
Journal:  J Lipid Res       Date:  2012-02-02       Impact factor: 5.922

3.  Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?

Authors:  Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2011-03-24       Impact factor: 5.922

4.  Hepatitis C virus and lipid profiles: more questions than answers?

Authors:  Ching-Sheng Hsu; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-07-29       Impact factor: 6.047

5.  Dietary unsaturated fat increases HDL metabolic pathways involving apoE favorable to reverse cholesterol transport.

Authors:  Allyson M Morton; Jeremy D Furtado; Carlos O Mendivil; Frank M Sacks
Journal:  JCI Insight       Date:  2019-04-04

6.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

Review 7.  Emerging Targets for Cardiovascular Disease Prevention in Diabetes.

Authors:  Nathan O Stitziel; Jenny E Kanter; Karin E Bornfeldt
Journal:  Trends Mol Med       Date:  2020-05-15       Impact factor: 11.951

8.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

Review 9.  From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.

Authors:  Frank M Sacks; Majken K Jensen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

10.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.